Clinical Trial Detail

NCT ID NCT01274338
Title Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

melanoma

Therapies

Ipilimumab

Interferon alpha-2b

Age Groups: child adult

No variant requirements are available.